Toronto Dominion Bank Acquires 4,008 Shares of Edwards Lifesciences Co. (NYSE:EW)

Toronto Dominion Bank grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 300,280 shares of the medical research company’s stock after purchasing an additional 4,008 shares during the period. Toronto Dominion Bank owned approximately 0.05% of Edwards Lifesciences worth $19,815,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Edwards Lifesciences by 9.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after acquiring an additional 40,348 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of Edwards Lifesciences by 2.8% during the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock valued at $168,597,000 after acquiring an additional 50,124 shares in the last quarter. AIA Group Ltd boosted its holdings in shares of Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after acquiring an additional 358,556 shares in the last quarter. RiverPark Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 58.1% during the 3rd quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock valued at $1,362,000 after acquiring an additional 7,583 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Edwards Lifesciences by 40.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 36,745 shares of the medical research company’s stock valued at $3,394,000 after acquiring an additional 10,492 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on EW shares. Morgan Stanley reissued an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 11th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Piper Sandler reduced their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Barclays upped their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Finally, Canaccord Genuity Group upped their target price on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $78.65.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $73.97 on Friday. The stock has a fifty day simple moving average of $69.09 and a two-hundred day simple moving average of $74.19. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market cap of $43.63 billion, a price-to-earnings ratio of 10.67, a price-to-earnings-growth ratio of 3.52 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.59 earnings per share. Analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock worth $2,323,150 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.